Previous 10 | Next 10 |
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi’s announcement of positive top-line data...
ROCKVILLE, MD, July 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its ...
2023-05-29 02:47:12 ET Summary MacroGenics demonstrates promise with its drug lorigerlimab for mCRPC treatment, despite a recent 18% stock price drop. Q1 2023 showed financial growth for the company, with doubled revenue and a narrower net loss compared to Q1 2022. FDA's appro...
2023-05-10 00:30:40 ET Image source: The Motley Fool. MacroGenics (NASDAQ: MGNX) Q1 2023 Earnings Call May 09, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: MacroGenics (MGNX) Q1 2023 Earnings Call Transcript
2023-05-09 20:16:05 ET MacroGenics, Inc. (MGNX) Q1 2023 Results Conference Call May 09, 2023 04:30 PM ET Company Participants Jim Karrels - Vice President, Chief Financial Officer Scott Koenig - President and CEO Conference Call Participants Jonathan Chan...
2023-05-09 16:27:10 ET MacroGenics press release ( NASDAQ: MGNX ): Q1 GAAP EPS of -$0.61 misses by $1.20 . Revenue of $24.5M (+120.7% Y/Y) misses by $71.66M . Shares -4.9% . Cash, cash equivalents and marketable securities as of March 31, 2023, wer...
ZYNYZ™ is third product approved in U.S. that originated from MacroGenics' pipeline Multiple Phase 2 programs advancing in metastatic castration-resistant prostate cancer (mCRPC) Cash runway through 2025 with $270 million in non-dilutive funding achieved over past nin...
2023-05-08 14:58:56 ET MacroGenics ( NASDAQ: MGNX ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, after market close. The consensus EPS Estimate is $0.35 (vs. -$1.08 last year) and the consensus Revenue Estimate is $96.16M (vs. $11.1M last year). Ov...
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial result...
ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that following the U.S. Food and Drug Administration...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...